12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Anzemet dolasetron regulatory update

FDA issued a drug safety communication warning that sanofi's IV Anzemet dolasetron should not be used to prevent nausea and vomiting associated with cancer chemotherapy (CINV) after...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >